Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ionis Earns $5M Biogen Milestone | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Ionis Earns $5M Biogen Milestone

Validates target to treat an undisclosed neurological disorder

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ionis Pharmaceuticals has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed target to treat an undisclosed neurological disorder under the companies’ strategic collaboration. For this newest target, Ionis will continue to evaluate the target with the goal of advancing the program into development.

“Our strategic collaboration with Biogen is very successful. Our most advanced program, nusinersen, is currently in Phase III studies, and we have a number of other drugs in development. We benefit tremendously from the expertise Biogen brings to our partnered programs. We also benefit financially as these programs advance. Across our four collaborations, we have generated more than $350 million from Biogen as our programs have advanced,” said B. Lynne Parshall, chief operating officer at Ionis. “As we enter 2016, we expect to continue to expand our collaboration with Biogen as we identify new targets and move new antisense drugs into development.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics